Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Cyclacel Pharmaceuti (CYCCP)

Cyclacel Pharmaceuti (CYCCP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 420 K
  • Annual Income, $ -22,555 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade CYCCP with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Latest Earnings Date N/A
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.25 +0.16%
on 05/03/24
19.07 -67.17%
on 04/04/24
-13.14 (-67.73%)
since 04/01/24
3-Month
6.25 +0.16%
on 05/03/24
21.47 -70.84%
on 02/14/24
-13.79 (-68.78%)
since 02/01/24
52-Week
5.25 +19.24%
on 11/08/23
22.20 -71.80%
on 02/01/24
-9.74 (-60.88%)
since 05/03/23

Most Recent Stories

More News
Cyclacel Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update

 - Oral fadraciclib demonstrated good tolerability with continuous dosing; anticipate entering Phase 2 POC stage in 2H 2022 –          - Demonstrated...

CYCC : 2.00 (-19.68%)
CYCCP : 6.26 (-12.32%)
Cyclacel Pharmaceuticals to Release Second Quarter 2022 Financial Results

BERKELEY HEIGHTS, N.J., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a...

CYCC : 2.00 (-19.68%)
CYCCP : 6.26 (-12.32%)
Cyclacel Pharmaceuticals Achieves Key Business Objectives in First Half of 2022 and Continues to Advance Clinical Pipeline

- Completed Enrollment in Phase 1 Dose Escalation with Oral Fadraciclib in Solid Tumors - - No Dose Limiting Toxicities Observed at All Dose Levels...

CYCC : 2.00 (-19.68%)
CYCCP : 6.26 (-12.32%)
Cyclacel Pharmaceuticals Announces That Kenneth M. Ferguson, Ph.D. Was Elected to Its Board of Directors

BERKELEY HEIGHTS, N.J., June 22, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a...

CYCC : 2.00 (-19.68%)
CYCCP : 6.26 (-12.32%)
Cyclacel Pharmaceuticals to Release First Quarter 2022 Financial Results

BERKELEY HEIGHTS, N.J., May 04, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a...

CYCC : 2.00 (-19.68%)
CYCCP : 6.26 (-12.32%)
Cyclacel Announces Dosing of First Patient in Phase 1/2 Study of Oral Cyc140 in Patients With Advanced Solid Tumors and Lymphomas

- CYC140, a Potent and Selective PLK1 Inhibitor to Be Evaluated as a Single Agent Across Multiple Solid Tumor and Lymphoma Types in Streamlined,...

CYCC : 2.00 (-19.68%)
CYCCP : 6.26 (-12.32%)
Cyclacel Pharmaceuticals Announces Publication Confirming Fadraciclib Suppresses MCL1 and Synergizes With Venetoclax in Chronic Lymphocytic Leukemia

-New Preclinical Data Highlight Fadraciclib’s Apoptosis Enabling Mechanism in Leukemia- -Remarkable Synergy Observed with Venetoclax, esp. in Resistant...

CYCC : 2.00 (-19.68%)
CYCCP : 6.26 (-12.32%)
Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results

-Initial Data from Phase 1/2 Study of Oral Fadraciclib in Solid Tumors Expected in First Half of 2022 –          -Cash Runway to Mid 2023- ...

CYCC : 2.00 (-19.68%)
CYCCP : 6.26 (-12.32%)
Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2021 Financial Results

BERKELEY HEIGHTS, N.J., March 22, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a...

CYCC : 2.00 (-19.68%)
CYCCP : 6.26 (-12.32%)
Cyclacel Pharmaceuticals Reviews 2021 Achievements And Announces Key Business Objectives for 2022

– Now Enrolling Patients in Two Registration-Directed Trials for Lead Candidate, Oral Fadraciclib – – Expecting Key Data Readouts for Oral...

CYCC : 2.00 (-19.68%)
CYCCP : 6.26 (-12.32%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Strengthening short term outlook on maintaining the current direction.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

CYCCP Dividends

Date Value
07/15/15 $0.1500
04/15/15 $0.1500
12/31/14 $0.1500
09/29/14 $0.1500
06/27/14 $0.1500
04/15/14 $0.1500
01/15/14 $0.1500
10/17/13 $0.1500
07/18/13 $0.1500
04/17/13 $0.1500
01/17/13 $0.1500
04/19/11 $0.1500
01/19/11 $0.1500
01/14/09 $0.1500
10/16/08 $0.1500
07/16/08 $0.1500
04/16/08 $0.1500
01/16/08 $0.1500
10/17/07 $0.1500
07/18/07 $0.1500
04/18/07 $0.1500
01/18/07 $0.1500
10/19/06 $0.1500
07/20/06 $0.1500
04/26/06 $0.1500
01/18/06 $0.1500
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar